Hospital General de Catalunya

Sant Cugat del Vallès 08195

0 studies enrolling now · 5 studies all time

What they study most

Adult-type Diffuse Gliomas, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor, Glioblastoma, HER2-Positive Primary Breast Cancer, Lung Adenocarcinoma Stage IIIB/IV, Macular Degeneration, Residual Invasive Breast Cancer, Solid Tumor, Adult

Studies at this site

• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations — Stopped early
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors — Stopped early
• Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD — Completed